Introduction
The viral protein apoptin has recently attracted increasing interest, because it can induce apoptosis in various human cancer cells, but not in normal cells, thus making it an interesting candidate for the development of novel anticancer strategies (Oro and Jans, 2004; Tavassoli et al., 2005) . Apoptin was originally identified as a 14 kDa product of the third open reading frame (VP3) of chicken anemia virus (CAV) (Noteborn et al., 1994) . Viral infection causes generalized lymphoid atrophy, severe anemia and increased mortality in young chickens by inducing apoptosis in thymocytes and erythroblastoid cells of the bone marrow (Adair, 2000) .
The tumor-selective cell death by apoptin has been demonstrated in a great number of tumor cells of different origin using several techniques including adenoviral transfer, transient overexpression or introduction of cell-permeable apoptin constructs (DanenVan Oorschot et al., 1997; Pietersen et al., 1999; Guelen et al., 2004; Burek et al., 2005) . Apoptin has also shown efficacy in treated xenografted tumors in mice and is being evaluated as an agent to destroy cancer cells selectively (van der Eb et al., 2002) . Apoptin induces apoptosis not only in tumor cells, but also in SV40-transformed fibroblasts or UV-irradiated cells from individuals with hereditary cancer-prone syndromes (Zhang et al., 1999) . Importantly, apoptin does not require p53, and moreover, has been reported to kill tumor cells by both Bcl-2-dependent and -independent processes (Zhuang et al., 1995; Schoop et al., 2004; Burek et al., 2005) .
In contrast to tumor cells, apoptin does not induce apoptosis in a variety of normal cells, including human endothelial cells, hepatocytes and hematopoietic stem cells (Oro and Jans, 2004) . Thus, the sensitivity of a tumor cell to apoptin presumably depends on alterations related to the transformed status of the cell. The mechanism by which apoptin is able to distinguish between tumor and normal cells is unknown, but seems to correlate with its cellular localization. In primary cells apoptin is retained in the cytoplasm, whereas in transformed cells it migrates into the nucleus (DanenVan Oorschot et al., 1997) . However, whereas nuclear localization in tumor cells seems to be important for apoptin-induced apoptosis, forced nuclear translocation is not sufficient for induction of apoptosis (Danen-Van Oorschot et al., 2003) . More recently, it was shown that apoptin is phosphorylated at Thr108 specifically in transformed cells, which facilitates the nuclear localization and tumor-specific activity of apoptin (Rohn et al., 2002) .
Both in intact cells and in cell-free systems, apoptin forms large DNA-binding globular aggregates of several apoptin subunits, which has been proposed as an essential feature of apoptin's proapoptotic activity (Leliveld et al., 2003a, b) . Intriguingly, upon entering the nucleus apoptin also forms distinct subnuclear aggregates, which appear as punctuate nuclear domains in immunofluorescence analyses (Burek et al., 2005) . Prominent nuclear bodies (NBs) are organized by the promyelocytic leukemia protein (PML) that is expressed as different isoforms generated by alternative splicing (Hofmann and Will, 2003) . PML was first discovered in patients with acute promyelocytic leukemia (APL), which is associated with a t(15;17) chromosomal translocation (Piazza et al., 2001) . The mutation leads to the expression of a dominant-negative fusion protein of PML and the retinoic acid receptor a (RARa). As a consequence and distinct from normal cells, PML-NBs are dissolved, and PML is dispersed into microspeckles in the nucleus and cytoplasm of APL cells.
PML-NBs have been implicated in a multitude of essential cellular functions including transcription, DNA repair, cell cycle regulation, microbial defense mechanisms and apoptosis (Bernardi and Pandolfi, 2003; Hofmann and Will, 2003; Dellaire and BazettJones, 2004) . In addition to PML, many regulators of apoptosis are recruited to PML-NBs including p53 and several p53 modifiers such as the Hdm2, Daxx and the p53 kinase HIPK2 (Hofmann and Will, 2003) . Direct evidence for a physiological involvement of PML and PML-NBs in apoptosis was revealed by the phenotypic analysis of PML À/À mice that are protected against a variety of apoptotic stimuli, including interferons, death ligands and g-irradiation (Wang et al., 1998a, b) . PML is therefore essential for both p53-dependent as well as p53-independent apoptotic programs. Most tumor cell lines express PML abundantly, and epithelial tumors have been reported to gradually increase PML levels, as the lesion progresses from benign dysplasia to carcinoma (Koken et al., 1995; Gurrieri et al., 2004) . However, in certain tumors PML protein is frequently lost and might be involved in tumor progression (Koken et al., 1995; Gurrieri et al., 2004) . Normal cells have a mostly weak constitutive PML expression that is strongly increased upon cellular stress (Koken et al., 1995) . For instance, viral infections upregulate PML and increase size and number of PML-NBs (Regad and Chelbi-Alix, 2001 ). In contrast, various viral proteins target PMLNBs for degradation (Everett, 2001) , suggesting that this process might facilitate viral replication or weaken the host antiviral response.
A major mechanism implicated in the targeting of proteins to PML-NBs is the post-translational covalent modification with small ubiquitin-like modifier (SUMO) proteins at lysine residues (Johnson, 2004; Hay, 2005) . PML itself is subject to SUMO modification which seems essential for the formation of mature PML-NBs (Kamitani et al., 1998) . Besides influencing the subcellular localization of a protein, covalent attachment of SUMO proteins can stimulate or repress transcriptional activity, regulate protein-protein interactions or prevent protein degradation through the ubiquitin-dependent pathway (Hay, 2005) . Analogous to the conjugation of ubiquitin, sumoylation proceeds in a three-step enzymatic process, involving a SUMO-activating enzyme E1, the conjugating E2 enzyme Ubc9 and different SUMO E3 ligases.
In the present study, we report for the first time the sumoylation and targeting of apoptin to the PML-NBs. We further identify that apoptin physically interacts with PML in PML-NBs. Using an apoptin mutant that has lost the capability to interact with PML we show that the interaction with PML is not required for apoptin's cytotoxic activity. Interestingly, apoptin was still able to induce apoptosis in the absence of PML protein and, furthermore, also efficiently killed PML cells lacking functional PML-NBs. Thus, our results suggest that the apoptosis-inducing activity of apoptin does not require nuclear aggregation in PMLNBs and might therefore be employed in the treatment of APL patients. Furthermore, we provide new insights into the physiological function of the viral protein apoptin.
Results

Apoptin interacts with PML and localizes to PML-NBs
Upon entry into the cell nucleus apoptin assumes a remarkably distinct speckled nuclear distribution that suggested a compartmentalization into subnuclear domains or NBs (Burek et al., 2005; Poon et al., 2005b) . As NBs organized by the PML protein have been implicated in apoptotic processes, we tested whether apoptin localizes to the PML-NBs in tumor cells. Indeed, when green fluorescent protein (GFP)-apoptin and the Flag-tagged PML isoforms III or IV were ectopically expressed in U2OS cells, immunofluorescence analysis revealed an extensive colocalization of apoptin and PML in the PML-NBs ( Figure 1a) . As the overexpression of PML might result in an artifactual accumulation of apoptin in the PML-NBs, we also analysed the localization of apoptin in cells expressing only endogenous PML proteins. Figure 1a demonstrates that the localization of apoptin and endogenous PML isoforms overlapped almost completely, indicating that the speckles formed by apoptin are closely associated or identical with PML-NBs.
As PML-NBs are composed of a multitude of different proteins, we set out to test whether the interaction of apoptin and PML may be direct in co-immunoprecipitation experiments. At 2 days after co-transfection of cells with His 6 -tagged apoptin and Flag-PML III, immunoprecipitation was carried out employing an anti-Flag antibody. Subsequent immunoblot analysis revealed a specific co-immunoprecipitation of apoptin by the anti-Flag antibody, which was only detectable in the presence, but not in the absence of Flag-PML III (Figure 1b) . Thus, apoptin and PML do not only colocalize in PML-NBs, but appear to interact directly with one another. In addition, the fact that apoptin also colocalized with the p53 kinase HIPK2, another PML-NB component (Figure 1c) , suggests that apoptin is actually localized in the PML-NBs instead of recruiting part of the PML protein into other subnuclear domains.
Apoptin is sumoylated in vitro and in vivo A frequent mechanism for relocating proteins to PMLNBs is the post-translational conjugation of SUMO. To explore whether this mechanism is employed by apoptin, we initially investigated whether apoptin is a substrate for sumoylation using an in vitro SUMO modification assay. To this end, apoptin was in vitro translated, radioactively labeled and then incubated with SUMO-1, SUMO-2 or GST-SUMO-1 and recombinant enzymes of the sumoylation machinery, that is, the SUMOactivating and -conjugating enzymes SAE1/2 and Ubc9, respectively. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of the reaction products revealed that a proportion of apoptin was converted to more slowly migrating forms (Figure 2a) . The apoptin forms with reduced mobility were only detectable in the presence of SUMO-1, SUMO-2 or GST-SUMO-1 and, furthermore, completely dependent on the presence of SAE1/2 and Ubc9. Moreover, substitution of GST-SUMO-1 for SUMO-1 alters the mobility of the more slowly migrating apoptin forms, confirming that the mobility shift is indeed a consequence of sumoylation. Although the efficiency of sumoylation is likely to be enhanced by the presence of a specific E3 ligase, the interaction of apoptin with Ubc9 and activated SUMO is sufficient for covalent attachment. Thus, these results demonstrate that SUMO proteins can be conjugated to apoptin in vitro.
To investigate whether apoptin is indeed also SUMOmodified in vivo, we first carried out immunofluorescence studies. U2OS cells that had been transfected with His 6 -apoptin, GFP-SUMO-1, -2 or -3 and the SUMOconjugating enzyme Ubc9 revealed a colocalization of apoptin with SUMO-1 and -2, in particular, and to a lesser extent with SUMO-3 ( Figure 2b ). To directly analyse whether apoptin is modified by SUMO in vivo, we co-transfected 293T cells with plasmids encoding His 6 -tagged apoptin, GFP-SUMO-1 or GFP-SUMO-2 and Ubc9. At 48 h after transfection, the cells were lysed directly in sample buffer to preserve SUMO modification. Immunoblotting of the lysates demonstrated that, in addition to the unmodified apoptin, more slowly migrating apoptin forms became detectable by the antiHis 6 antibody ( Figure 2c ). These high-molecular weight forms of apoptin did not appear in the absence of Ubc9 and either SUMO-1 or SUMO-2. Furthermore, reblotting with an anti-GFP antibody recognizing the ectopically expressed GFP-conjugated SUMO proteins revealed that the slowly migrating apoptin forms migrated with the same mobility as the SUMO-modified proteins. Again, these SUMO-modified protein bands were not detectable in the absence of apoptin, even when SUMO-1 or -2 and Ubc9 were present. Therefore, these experiments clearly demonstrate that apoptin is sumoylated in vitro and in vivo and that several SUMO moieties may be added per apoptin molecule. Apoptin is associated with PML-NBs K Janssen et al A sumoylation-deficient apoptin mutant does not interact with PML-NBs The majority of sumoylated proteins harbors the conserved Ubc9-binding motif CKxE (C, large hydrophobic residue; x, any amino acid), in which the lysine residue is targeted by SUMO modification (Rodriguez et al., 2001) . Other proteins, such as Huntingtin, Mdm2 or Daxx, lack this site but are nonetheless sumoylated in vivo at nonconventional sites (Ryu et al., 2000; Xirodimas et al., 2002; Steffan et al., 2004) . These unusual SUMO modifications are presumably mediated by additional contact sites between Ubc9 or SUMO and the substrate as well as by different recognition motifs bound by specific SUMO E3 ligases (Johnson, 2004) .
Sequence analysis revealed that apoptin also lacks a conserved CKxE sumoylation site (Figure 3a ), even though we had shown that it was sumoylated in vitro and in vivo. Nevertheless, we tried to identify the lysine residue of apoptin that is targeted by SUMO, and therefore exchanged all lysine residues of apoptin for arginines. Single mutations of the lysine residues, however, did not result in a loss of sumoylation or colocalization with the PML-NBs (data not shown), suggesting that apoptin can be sumoylated at least at two different, independent lysine residues. Interestingly, when we analysed different apoptin mutants we could identify a mutant that adapted a remarkably different subcellular distribution compared to the wild-type (wt) protein. This mutant differed from wt apoptin by the exchange of two isoleucines and one leucine residue for alanines (A 40 A 42 A 44 ) in apoptin's N-terminal leucinerich sequence (LRS) (Figure 3a) . Unlike wt apoptin that showed the typical speckled distribution in PML-NBs, the mutant was evenly dispersed throughout the nucleoplasm and accumulated partly in the nucleoli, but also stained the cytoplasm to some extent ( Figure 3b ). Furthermore, unlike the wt protein, mutant apoptin did no longer colocalize with either ectopically expressed PML III or endogenous PML proteins, as assessed in immunofluorescence studies (Figure 3b ).
This lack of interaction between the mutant apoptin and PML proteins was further substantiated by coimmunoprecipitation analyses (Figure 3c ). To this end, HEK 293T cells were transfected with a His 6 -and Myctagged mutant apoptin construct and Flag-tagged PML III. Immunoprecipitation of the lysates with an antiFlag antibody precipitated only Flag-PML III, but not the co-transfected mutant apoptin, as shown by Western blot analysis. Furthermore, precipitation of the His 6 /Myc-tagged mutant apoptin with either Ni-NTA beads or anti-Myc antibodies also did not result in a concomitant pull-down of PML III. Thus, in addition to the immunofluorescence analysis, these results confirmed the lack of interaction between the mutant apoptin and PML proteins.
We hypothesized that the lack of interaction between PML and mutant apoptin might be a consequence of disturbed post-translational modification with SUMO proteins. To test this, we co-transfected U2OS cells with the DsRed-tagged mutant apoptin and GFP-tagged SUMO constructs, and investigated the localization of S]methionine by in vitro translation. In vitro SUMO modification reactions employing labeled apoptin as substrate were carried out in the presence or absence of the purified components SUMO-1, SUMO-2, GST-SUMO-1, SAE1/2 and Ubc9. A negative control lacking these components was also analysed. Subsequent to the modification reaction the products were denatured and analysed by SDS-PAGE and phosphorimaging. (b) Apoptin colocalizes with SUMO proteins in vivo: U2OS cells were transfected with apoptin and expression constructs for GFP-SUMO-1, -2 and -3 and Ubc9. Immunofluorescent analysis was carried out 48 h after transfection. Apoptin was stained with a primary anti-apoptin antibody and Alexa 594-conjugated secondary antibody (red). SUMO-1, -2 and -3 were visualized by GFP fusion (green). DAPI (blue) was employed as nuclear counterstain. (c) Apoptin is sumoylated in vivo: HEK 293T cells were transfected with Myc/His 6 -apoptin and expression constructs for GFP-SUMO-1 or -2 and Ubc9 as indicated. After 48 h cells were lysed and separated on a 4-15% gradient polyacrylamide gel. The immunoblots were analysed employing anti-His 6 (upper panel) and reprobed with anti-GFP antibodies (lower panel).
Apoptin is associated with PML-NBs K Janssen et al the proteins by immunofluorescence analyses. Interestingly, in contrast to wt apoptin, the mutant isoform no longer colocalized with either of the coexpressed SUMO proteins (Figure 4a ). To verify that the mutant apoptin was indeed not sumoylated in vivo, cells were cotransfected with a Myc-and His 6 -tagged mutant or wt apoptin construct together with GFP-SUMO-1, -2 or -3 expression constructs and Ubc9 (Figure 4b ). Western blot analyses of the cell lysates with anti-GFP and antiHis 6 antibodies revealed that the mutant apoptin was detectable as a single protein band of 15 kDa corresponding to the size of monomeric, nonmodified apoptin. This expression pattern did not change upon co-transfection of any of the SUMO proteins or Ubc9. Under the same conditions, however, the wt protein was expressed as SUMO-modified, more slowly migrating forms, in addition to the unmodified protein. Furthermore, this modification was clearly dependent on the expression of SUMO and Ubc9. The results therefore suggest that, unlike the wt form, mutant apoptin is indeed not targeted by sumoylation, which is presumably mediated by a disturbed interaction of the mutant with either PML or Ubc9/SUMO. Interestingly, a SUMO binding motif consisting of a hydrophobic amino-acid stretch was recently identified (Song et al., 2005) , which is similar to the LRS of apoptin and Daxx (Chen et al., 2006) . Apart from mediating interactions with sumoylated proteins, this motif has been proposed to mediate sumoylation of proteins lacking the classical CKxE site by directly recruiting the Ubc9-SUMO thioester complex to those proteins. This mechanism could explain why mutation of this site results in deficient sumoylation of apoptin, although no lysine residues for SUMO conjugation are lost.
Cell death induction by apoptin is not compromised by lack of PML interaction To analyse whether the inability of the mutant apoptin protein to localize to PML-NBs affects cell death induction, we transfected wt or mutant apoptin into several human tumor cell lines, including the glioblastoma cell line T98, the fibrosarcoma cell line HT1080 and the mammary carcinoma cell line MCF-7/Caspase-3. Analysis of cell death induction over a time course of 72 h revealed that both mutant and wt apoptin achieved similar kill rates in all cell lines tested. This effect was independent of functional p53, as p53-mutated T98 cells ( Figure 5a ) were killed to a similar degree as the wt p53 MCF-7 and HT1080 cells (Figure 5b and c) . Furthermore, N-Ras, which is overexpressed in the HT1080 cells, did not impede the cell death by both apoptin isoforms. Therefore, apoptosis induction by apoptin does not require its interaction with PML or localization in PML-NBs. In addition, different from previous understanding even the nuclear aggregation of apoptin does not seem to be required, since the mutant apoptin that is diffusely distributed in the nucleus also efficiently kills the tumor cells. To substantiate these findings and to investigate whether the granular nuclear distribution of wt apoptin is actually dependent on PML proteins, we also transfected PML-deficient mouse embryonic fibroblasts and their wt counterparts with wt-GFP-apoptin. Figure 6a demonstrates that in PML À/À cells apoptin was delocalized in many tiny dots that were generally smaller and more abundant than PML-NBs. Such a socalled microspeckled distribution has been also found for other PML-NB components, such as SP100 or HIPK2, in PML-deficient cells (reviewed in Hofmann and Will, 2003) . A similar distribution was also detected after transfection of apoptin into the APL cell line NB4, Figure 3 Mutation of apoptin's N-terminal leucine-rich sequence prevents interaction with PML. (a) Protein sequences of wt and mutant apoptin: Apoptin harbors two basic sequences important for nuclear localization (NLSs -amino acids 82-88 and 111-121, respectively), and a leucine-rich sequence (LRS -amino acids 33-46). In the mutant protein, a leucine and two isoleucine residues of the LRS were substituted by alanines. Apoptin contains no CKxE-consensus recognition sequence for sumoylation. Lysine residues that could be covalently linked to SUMO proteins, are marked by asterisks. (b) Subcellular localization of mutant apoptin: U2OS cells were transfected with GFP-mt-apoptin and Flag-PML III or GFP-mt-apoptin alone, and stained for immunofluorescence microscopy 48 h after transfection. Apoptin was visualized as a GFP fusion (green). Ectopically expressed PML III was stained using anti-Flag antibody and Alexa 594-conjugated secondary antibody (red), with endogenous PML proteins visualized using anti-PML and Alexa 594-conjugated secondary antibodies. Nuclei were counterstained with DAPI (blue). In contrast to the aggregation of wt-apoptin in nuclear speckles (Figure 1a) , mutant apoptin was evenly distributed throughout the nucleoplasm and partially localized in the cytoplasm. (c) Lack of co-immunoprecipitation of transfected Myc/His 6 -mt-apoptin and Flag-PML III: immunoprecipitation was carried out 48 h after transfection of 293T cells employing Ni-NTA beads (Ni), anti-Flag M2-agarose (Flag), or anti-Myc and protein G sepharose (Myc). Apoptin and Flag-PML III were visualized in the cell lysates (L) and the different precipitates by immunoblot analysis using anti-His 6 and anti-Flag antibodies, respectively. Unlike wt-apoptin (see Figure 1b) , mt-apoptin does not interact with PML (lower panel). Asterisks denote the position of the IgG heavy (upper panel) and light chain (lower panel), respectively.
Apoptin is associated with PML-NBs K Janssen et al which expresses a nonfunctional PML-RARa fusion protein and forms no PML-NBs (data not shown). Importantly, wt apoptin-induced cell death in PML À/À mouse embryonic fibroblasts as efficiently as in PMLexpressing cells, and also killed NB4 cells (Figure 6b  and c) . Thus, the death-inducing activity of apoptin is clearly independent of PML expression and localization in PML-NBs.
Discussion
Successful cancer therapy relies on tumor cell specificity. Apoptin has been reported to induce the selective death of tumor cell lines derived from diverse human tumors including melanoma, hepatoma, lymphoma, cholangiocarcinoma, colon carcinoma and breast and lung cancer. In contrast, apoptin does not induce apoptosis in Apoptin is associated with PML-NBs K Janssen et al normal, nontransformed cells such as fibroblasts, keratinocytes or smooth muscle cells (Oro and Jans, 2004) . The manner by which apoptin is able to distinguish between tumor and normal cells remains to be elucidated. The subcellular localization of apoptin may be important for induction of cell death. In cells resistant to apoptin-mediated cell death the protein has a cytoplasmic localization, whereas in sensitive cells it is found in the nucleus (Danen-Van Oorschot et al., 1997) . Recently, apoptin was described to be specifically phosphorylated in tumor and transformed cells by an unknown kinase, which was proposed to be important for the nuclear localization and cell killing ability of apoptin (Rohn et al., 2002) . However, it was also shown that a C-terminally truncated apoptin construct, in which the phosphorylation site was deleted, was still able to translocate to the nucleus and induce apoptosis (Guelen et al., 2004) . Thus, the interaction with other molecules or additional modifications of apoptin that are not present in nontransformed cells may be required for apoptin's selective cytotoxicity.
In the present study, we hypothesized that sumoylation of apoptin and its interaction with PML proteins might be required for the cytotoxic activity of apoptin and involved in tumor cell specificity. We show that upon entering the nucleus of transformed cells apoptin assumes a granular distribution that greatly resembles the pattern of PML-NBs. Furthermore, we show that apoptin colocalizes with PML-NBs and interacts directly with endogenous PML. Similar as described for other PML-NB components, in PML-deficient cells and in cells expressing the dominant-negative PMLRARa fusion protein apoptin still formed microspeckled aggregates, suggesting that PML proteins are not required for nuclear aggregation of apoptin. More importantly, we demonstrate that the interaction with PML does not influence the proapoptotic activity of apoptin, as very similar cell death rates were obtained in both PML þ / þ and PML À/À cells. Although apoptin's interaction with PML therefore appears dispensable for apoptosis, it might be speculated that it is involved in viral replication. CAV has a very small genome encoding only the three proteins: the structural protein VP1, the cytoplasmic dual specificity protein phosphatase VP2 and apoptin (VP3). Renshaw et al. (1996) analysed different field isolates of the virus and found striking differences in viral replication and spreading efficiency in different chicken T-cell lines, which they assumed to be due to mutations in the NLS of apoptin, leading to a cytoplasmic instead of a nuclear expression. Also, site directed-mutagenesis of VP2 resulted in cytoplasmic restriction of apoptin, which was associated with reduced viral replication and cytopathogenicity of CAV in infected chicken cells (Peters et al., 2006) . Therefore, a nuclear localization of apoptin seems to be necessary not only for efficient apoptosis induction, but also for viral replication. Apoptin is associated with PML-NBs K Janssen et al An association of apoptin with PML-NBs might be supportive for this function, as many DNA viruses establish their replication centers at the PML-NBs (Everett, 2001) . Several Herpes viruses encode proteins that disrupt the PML-NBs, probably in order to make use of transcription factors stored therein. Association with apoptin, in contrast, does not lead to an altered morphology of PML-NBs or degradation of PML, which is similar to other viral proteins such as SV40 large T antigen (Ishov and Maul, 1996) . Further, SV40 replicates in PML-NBs, but does not disrupt the subnuclear structure.
A frequent mechanism for targeting cellular proteins to PML-NBs is their covalent attachment to SUMO proteins. Our results demonstrate that apoptin can be sumoylated both in vitro and in vivo. In the majority of cases so far analysed, SUMO modification is substoichiometric, and only a fraction of the target protein can be detected in its sumoylated form. This is also the case for apoptin. The low stoichiometry might be caused by the well-documented difficulty in isolating SUMO-modified proteins as well as by the very transient and dynamic nature of SUMO modification, which in addition is controlled by several SUMO proteases (Muller et al., 2001) . Interestingly, we found that mutant apoptin, which had lost its ability to interact with PML, was also deficient in undergoing SUMO modification. It is therefore conceivable that sumoylation of apoptin is a prerequisite for its targeting to the PML-NBs. On the other hand, sumoylation could also occur following association of apoptin with PML. If in vivo an E3 ligase is necessary, PIAS1, a constituent of PML-NBs, is a good candidate for enhancing sumoylation of apoptin upon entering the NBs (Johnson, 2004) . Alternatively, sumoylation of apoptin could take place during its nuclear translocation by the SUMO E3 ligase RanBP2/Nup358 that is part of the nucleocytoplasmic transport machinery (Pichler et al., 2002) . Sumoylation by RanBP2 upon nucleo-cytoplasmic shuttling is a common mechanism for the subsequent nuclear retention of several cellular and viral proteins. A prerequisite for an interaction with RanBP2 and a subsequent sumoylation of a target protein is a functional NLS (Rodriguez et al., 2001) , which is also present in apoptin. In fact, we show that sumoylationdeficient apoptin was also partly localized in the cytoplasm and was less strongly retained in the nucleus than the wt protein.
The N-terminal LRS of apoptin, which, when mutated, eliminates sumoylation, does not harbor lysine residues able to be SUMO-modified. Hence, the sumoylation defect of the mutant is presumably indirect, for instance, through inhibiting the binding of Ubc9/ SUMO or a putative E3 ligase to apoptin or by abrogating its recruitment to PML-NBs. It is possible and supported by our present results that the LRS functions as a nuclear speckle retention sequence by mediating an association with PML-NBs. If PML-NB localization is a prerequisite for sumoylation, this may explain why the mutant is not sumoylated, since it fails to bind PML and does not localize in the PML-NBs.
The LRS has been implicated in the multimerization of apoptin, which forms globular aggregates comprising up to 30-40 subunits (Leliveld et al., 2003b ). Apoptin's multimerization has been suggested to be essential for its proapoptotic activity. In the present study, we have not analysed the multimerization state of the different apoptin versions. Our finding that the apoptin mutant, which does not form nuclear aggregates, is still cytotoxic similar to the wt protein, however, would argue against this hypothesis.
In summary, our study identifies PML and SUMO proteins as new interaction partners of apoptin. Interestingly, neither a mutant incapable of interacting with PML nor the lack of functional PML expression compromised the ability of apoptin to induce apoptosis in tumor cells. As apoptin is a promising lead agent that rather specifically induces cell death in tumor cells, our results also imply that tumor cells of APL patients lacking PML-NBs could still respond to apoptin treatment. Further experiments will have to show whether the interaction with PML and the SUMO modification of apoptin also interferes with the replication and spread of CAV under physiological conditions.
Material and methods
Cell culture and transfections HT1080 human fibrosarcoma, T98 glioblastoma, MCF-7/ Caspase-3 breast carcinoma and APL-derived NB4 cells were maintained in Roswell's Park Memorial Institute (RPMI)-1640 medium supplemented with 10% heat-inactivated fetal calf serum, 100 units/ml penicillin and 0.1 mg/ml streptomycin (all from PAA Laboratories, Linz, Austria). Human embryonic kidney HEK 293T cells, U2OS osteosarcoma cells, and wt and PML À/À mouse embryonic fibroblasts (MEFs) were maintained in Dulbecco's modified Eagle's medium supplemented as described above. Transient transfections were carried out either by calcium phosphate precipitation, electroporation or by using Optifect (Qiagen GmbH, Hilden, Germany), Lipofectamine (Invitrogen, Karlsruhe, Germany) or Fugene 6 (Roche, Mannheim, Germany) according to the manufacturers' instructions.
Expression constructs and antibodies
Wt apoptin was cloned into peGFP-C1 and pDsRed1-C1 (Clontech, Palo Alto, CA, USA) as described (Burek et al., 2005) or inserted into the BamHI and XbaI sites of pcDNA 3.1/Myc-His (Invitrogen). Mutant apoptin constructs were derived from wt-apoptin encoding plasmids by site-directed mutagenesis (Poon et al., 2005a) . Mutant apoptin was furthermore cloned into the KpnI and XhoI sites of pcDNA4/Myc-His (Invitrogen). Expression constructs for PML III, PML IV, HIPK2, SUMO-1, -2, -3, SAE1, SAE2 and Ubc9 have been previously described (Fogal et al., 2000; Tatham et al., 2001; Hofmann et al., 2002) . The following mouse monoclonal antibodies were used: anti-apoptin (clone 85.1; generously provided by M Noteborn), anti-PML (PG-M3; Santa Cruz Biotechnology, Santa Cruz, CA, USA), antiFlag (M2; Sigma-Aldrich, Steinheim, Germany), anti-His 6 (BioCheck, Mu¨nster, Germany), anti-GFP (B-2; Santa Cruz Biotechnology), and anti-c-Myc (9E10; Santa Cruz Biotechnology).
Immunofluorescence staining
Immunofluorescence analyses were performed as described (Hofmann et al., 2002) using mouse anti-PML, anti-Flag, antiapoptin and Alexa-594-coupled chicken anti-mouse IgG (Molecular Probes, Invitrogen). DNA was visualized by 4,6-diamidino-2-phenylindole (DAPI) staining and examined with an epifluorescence microscope (Axioplan-2, Zeiss, Jena, Germany).
Immunoblotting Cells were lysed in Totex buffer (20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid, pH 7.9, 350 mM NaCl, 20% glycerol, 1% NP-40, 1% SDS, 1 mM MgCl 2 , 0.5 mM ethylenediamine-N,N,N 0 ,N 0 -tetraacetic acid, 0.1 mM ethylene glycolbis-(2-aminoethyl ether)-N,N,N 0 ,N 0 -tetraacetic acid, 10 mM N-ethylmaleimide, complete protease inhibitor cocktail). The lysates were then separated on 15% linear or 4-15% gradient polyacrylamide gels and subsequently transferred to hybond polyvinylidene difluoride membranes (Amersham Biosciences, Uppsala, Sweden). After blocking with 5% bovine serum albumin in phosphate-buffered saline (PBS)/0.05% Tween-20, membranes were incubated with the primary antibodies overnight at 4 o C. Following washing with PBS/0.5% Tween-20 the membranes were incubated for 1 h with horseradish peroxidase-coupled goat anti-mouse IgG (Promega, Mannheim, Germany). After extensive washing, the reaction was developed by enhanced chemiluminescent staining .
Co-immunoprecipitation
Transfected HEK 293T cells were lysed by sonification in Totex buffer. After removal of cell debris the samples were diluted with SDS-free lysis buffer to a final concentration of 0.1% SDS and then precipitated overnight using either 25 ml Flag-M2-agarose (Sigma-Aldrich), Ni-NTA beads (Qiagen), or 1 mg of anti-c-Myc antibody and 25 ml of Protein G sepharose (Sigma-Aldrich). After three washes in lysis buffer, precipitates were denatured in standard 2 Â SDS sample buffer, separated on SDS-PAGE gels (15%) and analysed by immunoblotting.
In vitro and in vivo SUMO conjugation assays For in vitro SUMO conjugation assays SUMO-1, SUMO-2, GST-SUMO-1, Ubc9 and SAE1/SAE2 were expressed in and purified from Escherichia coli B834 as described (Girdwood et al., 2003) . [
35 S]methionine-labeled apoptin was generated in a wheat germ-coupled transcription/translation system according to the manufacturer's instructions (Promega). SUMO conjugation assays were carried out essentially as described (Girdwood et al., 2003) and analysed by SDS-PAGE. For in vivo SUMO conjugation assays 5 Â 10 5 HEK 293T cells were transfected with expression constructs for wt-and mt-apoptin along with GFP-SUMO-1, -2 or -3 and HA-Ubc9 as indicated. At 2 days after transfection cells were directly lysed in 2x SDS sample buffer, and equal amounts of lysate were analysed by SDS-PAGE and immunoblotting.
Cell death assays Cell death was quantified by flow cytometry or microscopical analysis (Burek et al., 2005; Engels et al., 2005) . After transfection, cells were stained with propidium iodide (2 mg/ ml) for 10 min at room temperature and subsequently analysed in the Fl-2 channel of a FACSCalibur flow cytometer equipped with Cell Quest II-software (Becton Dickinson, Heidelberg, Germany). wt and PML À/À MEFs were transfected with the GFP-apoptin expression constructs employing Optifect transfection reagent. At 2 days after transfection cells were stained with the fluorescent DNA dye Hoechst 33342 and examined microscopically for apoptotic nuclear condensation. At least 400 GFP-positive cells were scored for each condition, and the percentage of apoptotic cells (condensed nuclei) and vital cells (intact nuclei) was determined.
